Why the study?
Conventional triglyceride-lowering therapies have limited efficacy in reducing triglycerides, pancreatitis, or ASCVD in severe hypertriglyceridemia, and the role of novel APOC3 inhibition in ASCVD prevention remains unproven.
Do APOC3-targeted therapies reduce triglycerides and the risk of acute pancreatitis and ASCVD in patients with severe hypertriglyceridemia and familial chylomicronemia syndrome?
Do APOC3-targeted therapies reduce triglycerides and the risk of acute pancreatitis and ASCVD in patients with severe hypertriglyceridemia and familial chylomicronemia syndrome?
APOC3-targeted therapies effectively reduce triglycerides and acute pancreatitis risk in familial chylomicronemia syndrome, but their impact on ASCVD prevention requires further study.
No takes yet. Share an insight, caveat, or question.
Supports pancreatitis prevention in FCS; leaves open ASCVD prevention pending dedicated trials.
Sotirios Tsimikas (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: